

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JW

<b>TRANSMITTAL</b> <b>OVERFORM</b> DEC 11 2006 (to be used for all correspondence after initial filing)	Application Number	10/559,148
	Filing Date	August 17, 2006
	First Named Inventor	Jane Louise HOLLEY
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	41577/323890

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08 (01 sheet) 2. 09 publications
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Kilpatrick Stockton LLP		
Signature	<i>Dean W. Russell</i>		
Printed Name	Dean W. Russell		
Date	5 DECEMBER 2006	Reg. No.	33,452

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the U.S. Postal Service in an envelope marked as first class mail addressed to Mail Stop Amendment, U.S. Patent and Trademark Office, P. O. Box 1450, Alexandria, Virginia 22313-1450 on the date indicated below.			
Signature	<i>Angela M. Rossi</i>		
Typed or printed name	Angela M. Rossi	Date	05 DECEMBER 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jane Louise HOLLEY

SERIAL NO.: 10/559,148 Group Art Unit:

FILED: August 17, 2006 EXAMINER:

FOR: COMPOSITIONS COMPRISING LARGE AND SMALL BINDING  
FRAGMENTS OF ANTIBODIES AGAINST THE SAME TOXIN

ATTORNEY DOCKET NO. 41577/323890

DATE: 05 DECEMBER 2006

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

---

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the modified Form PTO/SB/08 are cited for consideration by the Examiner.

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. 1.97(b), before issuance of a first Office action on the merits. Applicant believes that no fee is due for

submission and consideration of this paper. The Commissioner is authorized to charge any fees associated with this filing or credit any overpayment to Deposit Account No. 11-0855.


Respectfully submitted,



---

Dean W. Russell  
Reg. No. 33,452

KILPATRICK STOCKTON LLP  
Suite 2800, 1100 Peachtree Street  
Atlanta, Georgia 30309-4530  
(404) 815-6528



Substitute for form 1449A PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/559,148
Filing Date	August 17, 2006
First Named Inventor	Jane Louise HOLLEY
Art Unit	
Examiner Name	
Attorney Docket Number	41577/323890

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Behr, et al., 'Anti-Carcinoembryonic antigen Antibodies versus Somatostatin Analogs in the Detection of Metastatic Medullary Thyroid Carcinoma,' <i>Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer</i> , Supplement to <i>Cancer</i> , pp. 2436-2457 (1997)	
		Hibbs, et al., 'Experience with the Use of an Investigational F(ab') <sub>2</sub> Heptavalent Botulism Immune Globulin of Equine Origin During an Outbreak an Outbreak of Type E Botulism in Egypt,' <i>Clinical Infectious Diseases</i> , 23:337-340 (1996)	
		Ismail, et al., 'Pharmacokinetics of <sup>125</sup> I-Labelled IgG, F(ab') <sub>2</sub> and Fab Fractions of Scorpion and Snake Antivenins: Merits and Potential for Therapeutic Use,' <i>Toxicon</i> , 36(11):1523-1528 (1998)	
		Mayers, et al., 'Anti-immunoglobulin Responses to IgG,F(ab') <sub>2</sub> , and Fab Botulinum Antitoxins in Mice,' <i>Immunopharmacology and Immunotoxicology</i> , 25(3):397-408 (2003)	
		Mayers, et al., 'Antitoxin therapy for botulinum intoxication,' <i>Reviews in Medical Microbiology</i> , 12(1):29-37 (2001)	
		Muller, et al., 'Phage-displayed and soluble mouse scFv fragments neutralize rabies virus,' <i>Journal of Virological Methods</i> , 67:221-233 (1997)	
		Steele, et al., 'Further Evidence for Cross-Linking as a Protective Factor in Experimental Cholera: Properties of Antibody Fragments,' <i>The Journal of Infectious Diseases</i> , 132(2):175-180 (1975)	
		Vassilev, et al., 'Protective Activity of Two Human Intravenous Immunoglobulin Preparations in Experimental Infection with an Encapsulated Staphylococcus Aureus Strain,' <i>Acta Microbiologica Hungarica</i> , 34(2):139-145 (1987)	
		Vaz, et al., 'Higher protective activity of Fab' fragment compared to F(ab') <sub>2</sub> and IgG on experimental tetanus,' <i>Mircen Journal of Appl. Microbiol. &amp; Biotech.</i> , 4(3):339-348 (1988)	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.